History of company
Founding and Platform Development
2010: Alphamer IP acquired from Nobel Laureate Dr Kary Mullis and initial investment from high net worth individuals
2011: R&D begins, collaboration with USCD (Prof. Victor Nizet)
2015: Publication of first in vitro proof of concept that alphamers have the potential to redirect pre-existing antibodies and trigger an immediate antibacterial immune response ( J MolMed DOI 10.1007/s00109-015-1280-4).
2015: Current Executive Management team formed with Mike Westby as CEO and Clive Dix as Chairman
2016: Avvinity collaboration with initiated with Horizon Discovery PLC, including an initial £2.8m investment to progress oncology R&D
2017: Innovate UK’s Biomedical Catalyst (BMC) programme award to co-fund research focused on antimicrobial resistance
2018: Additional investment by Horizon Discovery following achievement of oncology milestones
2019: CARB-X award to co-fund research into antibacterial molecules